
|Slideshows|February 2, 2017
Antipsychotic Augmentation vs Monotherapy in Schizophrenia
Author(s)Brian Miller, MD, PhD, MPH
To augment or not to augment? That is the question.
Advertisement
View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation
2
Assessing Antipsychotics as Antidepressant Adjuncts
3
Future DSM Plans Overlook Core Problem of Validity
4
Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease
5










